#154772

Anti-Bone Marrow Cell [GEPI]

Cat. #154772

Anti-Bone Marrow Cell [GEPI]

Cat. #: 154772

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 10-12 weeks

Target: Bone Marrow Cell

Class: Monoclonal

Application: FACS ; IHC ; IF ; IP

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Netherlands Cancer Institute

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-Bone Marrow Cell [GEPI]
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IF ; IP
  • Description: Bone marrow is a semi-solid tissue which may be found within the spongy or cancellous portions of bones. In birds and mammals, bone marrow is the primary site of new blood cell production or haematopoiesis. It is composed of hematopoietic cells, marrow adipose tissue, and supportive stromal cells.
  • Immunogen: The mouse was immunized with human bone marrow cells
  • Isotype: IgM
  • Myeloma used: Sp2/0-Ag14

Target Details

  • Target: Bone Marrow Cell
  • Target background: Bone marrow is a semi-solid tissue which may be found within the spongy or cancellous portions of bones. In birds and mammals, bone marrow is the primary site of new blood cell production or haematopoiesis. It is composed of hematopoietic cells, marrow adipose tissue, and supportive stromal cells.

Applications

  • Application: FACS ; IHC ; IF ; IP

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Keizer et al. 1986. J Immunol Methods. 95(1):141-7. PMID: 3782823.